Spatial transcriptomics in breast cancer reveals tumour microenvironment-driven drug responses and clonal therapeutic heterogeneity
NAR Cancer · 03.10.2024 · 6 (4)
DOI: 10.1093/narcan/zcae046 ↗Kurz gefasst
Fachartikel in der Zeitschrift NAR Cancer, online erschienen am 18.12.2024. Verfasst von María José Jiménez-Santos und 4 weiteren Autor:innen. Beteiligte Einrichtung: Bioinformatics Unit, Spanish National Cancer Research Centre (CNIO), Calle Melchor Fernández Almagro, 3, Madrid 28029, Spain. Die Arbeit wurde bisher 32-mal zitiert (Crossref) und nennt 94 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: ERDF, Ministerio de Ciencia e Innovación, Agencia Estatal de Investigación.
Abstract (Originalsprache)
Breast cancer patients are categorized into three subtypes with distinct treatment approaches. Precision oncology has increased patient outcomes by targeting the specific molecular alterations of tumours, yet challenges remain. Treatment failure persists due to the coexistence of several malignant subpopulations with different drug sensitivities within the same tumour, a phenomenon known as intratumour heterogeneity (ITH). This heterogeneity has been extensively studied from a tumour-centric view, but recent insights underscore the role of the tumour microenvironment in treatment response. Our research utilizes spatial transcriptomics data from breast cancer patients to predict drug sensitivity. We observe diverse response patterns across tumour, interphase and microenvironment regions, unveiling a sensitivity and functional gradient from the tumour core to the periphery. Moreover, we find tumour therapeutic clusters with different drug responses associated with distinct biological functions driven by unique ligand-receptor interactions. Importantly, we identify genetically identical subclones with different responses depending on their location within the tumour ducts. This research underscores the significance of considering the distance from the tumour core and microenvironment composition when identifying suitable treatments to target ITH. Our findings provide critical insights into optimizing therapeutic strategies, highlighting the necessity of a comprehensive understanding of tumour biology for effective cancer treatment.
Autor:innen und Institutionen
- Bioinformatics Unit, Spanish National Cancer Research Centre (CNIO), Calle Melchor Fernández Almagro, 3, Madrid 28029, Spain.
- Lung-H120 Group, Spanish National Cancer Research Centre (CNIO), Calle Melchor Fernández Almagro, 3, Madrid 28029, Spain.
ORCID-Profile: María José Jiménez-Santos, Santiago García-Martín, Marcos Rubio-Fernández, Gonzalo Gómez-López, Fátima Al-Shahrour
Förderung
- ERDF
- Ministerio de Ciencia e Innovación
- Agencia Estatal de Investigación
- European Union, European Regional Development Fund
- Comunidad de Madrid, European Structural and Investment Funds
- Horizon Europe Framework Programme
- Fundación científica de la Asociación Española Contra el Cáncer
- ‘la Caixa’ Foundation
Zitieren
APA
Jiménez-Santos, M. J., García-Martín, S., Rubio-Fernández, M., Gómez-López, G., & Al-Shahrour, F. (2024). Spatial transcriptomics in breast cancer reveals tumour microenvironment-driven drug responses and clonal therapeutic heterogeneity. NAR Cancer, 6(4). https://doi.org/10.1093/narcan/zcae046
Vancouver
Jiménez-Santos MJ, García-Martín S, Rubio-Fernández M, Gómez-López G, Al-Shahrour F. Spatial transcriptomics in breast cancer reveals tumour microenvironment-driven drug responses and clonal therapeutic heterogeneity. NAR Cancer. 2024;6(4). doi:10.1093/narcan/zcae046
BibTeX
@article{JimnezSantos2024,
author = {Jiménez-Santos, María José and García-Martín, Santiago and Rubio-Fernández, Marcos and Gómez-López, Gonzalo and Al-Shahrour, Fátima},
title = {Spatial transcriptomics in breast cancer reveals tumour microenvironment-driven drug responses and clonal therapeutic heterogeneity},
journal = {NAR Cancer},
year = {2024},
volume = {6},
number = {4},
doi = {10.1093/narcan/zcae046}
}
EUVIMED